Case Reports in Oncological Medicine最新文献_第4页

First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor. 首次描述阿伐替尼对散发性肠系膜蝶形细胞瘤的临床活性

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2024-08-05 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8684418

Rebecca Ganzon, Wei Chen, Gabriel Tinoco

{"title":"First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor.","authors":"Rebecca Ganzon, Wei Chen, Gabriel Tinoco","doi":"10.1155/2024/8684418","DOIUrl":"10.1155/2024/8684418","url":null,"abstract":"Desmoid tumors (DTs) are rare and locally aggressive with a high rate of local recurrence even with optimal surgical resection. Systemic treatments are often utilized for desmoid cases with high risk of surgical morbidity or for local and symptomatic control of recurrent disease. However, the systemic treatment options for DTs are limited with limited responses. Avapritinib is a tyrosine kinase inhibitor (TKI) approved in 2020 for adults with unresectable or metastatic gastrointestinal (GI) stromal tumors (GISTs) harboring a platelet-derived growth factor receptor alpha (PDGFRA) Exon 18 mutation, including D842V mutations. In this case report, we describe a 55-year-old man with a history of D842V-mutant gastric GIST who presented several years after complete resection of the GIST with an enlarging soft tissue mass in the small intestine. After a nondiagnostic biopsy, the patient was started on avapritinib due to concerns for recurrent D842V-mutant GIST. The tumor had a partial response to treatment by RECIST 1.1 criteria, and the patient underwent surgical resection. The final pathology report revealed a sporadic DT. To our knowledge, this is the first known description of the activity of avapritinib in the treatment of a sporadic mesenteric DT, which is relevant given the limited treatment options for patients with this diagnosis. This clinical finding may be worth exploring in a dedicated clinical trial.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2024 ","pages":"8684418"},"PeriodicalIF":0.6,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudomyxoma Peritonei in a Case of Carcinoma Cervix: Subtle Finding With Implications on Management and Prognosis. 宫颈癌病例中的假性腹膜肌瘤：微妙发现对治疗和预后的影响

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2024-08-01 eCollection Date: 2024-01-01 DOI: 10.1155/2024/3066063

Sarita Kumari, Suvidya Singh

引用次数: 0

Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 1: A Boy Presenting With Priapism and Loss of Vision. 国际骨髓增生性白血病基金会 (iCMLf) 专家讨论的资源有限国家患者治疗病例 - 病例 1：一名出现尿崩症和视力丧失的男孩。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.1155/2024/5534445

Nirmalya Roy Moulik, Arlene Harriss-Buchan, Guiseppe Saglio, Nicola Evans, Meinolf Suttorp

{"title":"Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 1: A Boy Presenting With Priapism and Loss of Vision.","authors":"Nirmalya Roy Moulik, Arlene Harriss-Buchan, Guiseppe Saglio, Nicola Evans, Meinolf Suttorp","doi":"10.1155/2024/5534445","DOIUrl":"10.1155/2024/5534445","url":null,"abstract":"Pediatric chronic myeloid leukemia (pCML) is a rare malignancy accounting for only 2%-3% of all childhood leukemias. Due to this rarity, familiarity with pCML is limited among most pediatric practitioners, including even pediatric hemato-oncologists. In low- and middle-income countries (LMICs), limited financial resources and limited data specific to pCML represent obstacles that healthcare providers must face in diagnosing and treating this rare condition in children. The International CML Foundation (iCMLf) is improving outcomes for people with CML in these countries where resources, diagnostics, and access to medicines may be limited (https://www.cml-foundation.org/lmic-programs.html). Virtual meetings with the purpose of teaching participating pediatricians from LMICs of defined geographical regions were organised by the iCMLf in 2023. At a virtual meeting of the South Asia region, the case of a 14-year-old Indian boy was presented diagnosed with CML in a chronic phase complicated by priapism and loss of vision in his left eye due to hyperleukocytosis. Key aspects of this case are discussed in-depth from the perspective of (i) a pediatric hemato-oncologist practicing in a high-income country, (ii) a pediatric hemato-oncologist practicing in a LMIC, (iii) an adult CML hematologist, and (iv) from the iCMLf in improving the care of children with CML worldwide. Thus by discussing a multifaceted complicated case of pCML in written form as well as pointing to the pediatric module of the iCMLf Knowledge Centre will hopefully contribute to minimize existing knowledge gaps in a rare pediatric malignancy.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2024 ","pages":"5534445"},"PeriodicalIF":0.6,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Primary Telangiectatic Mandibular Osteosarcoma With Germ-Line Malignancy-Associated DNA Damage Repair Gene Polymorphisms: A Case Report. 与生殖系恶性肿瘤相关的 DNA 损伤修复基因多态性的原发性下颌骨远端切除性骨肉瘤：病例报告。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.1155/2024/2418888

Muhammad Tahir, Eric X Wei, Carlina Madelaire, Alice S Yu, Guillermo A Herrera, Rodney E Shackelford

{"title":"A Primary Telangiectatic Mandibular Osteosarcoma With Germ-Line Malignancy-Associated DNA Damage Repair Gene Polymorphisms: A Case Report.","authors":"Muhammad Tahir, Eric X Wei, Carlina Madelaire, Alice S Yu, Guillermo A Herrera, Rodney E Shackelford","doi":"10.1155/2024/2418888","DOIUrl":"10.1155/2024/2418888","url":null,"abstract":"Primary mandibular telangiectatic osteosarcomas are very rare lesions, with only nine cases reported. Histologically, these lesions show multiple cystic blood-filled cavities traversed by neoplastic bone in septa lined by high-grade malignant cells. Here, we report an 81-year-old woman who presented with a mandibular mass, which was surgically resected and analyzed by histologic examination and whole exome DNA sequencing. A diagnosis of telangiectatic osteosarcoma was given. Comparative sequencing data analysis of paired benign and tumor DNA revealed 1577 variants unique to the tumor DNA, which clustered into several gene families, including those regulating DNA repair and apoptosis. Comparison of benign and tumor DNA revealed many shared gene polymorphisms associated with an increased cancer risk. These included polymorphisms in the ATM, p53, BRCA1, and BRCA2 and many other genes. Interestingly, the patient's family history showed an unusually high cancer incidence, likely related to these cancer risk-associated polymorphisms. To our knowledge, this is the first-time sequencing applied to a mandibular telangiectatic osteosarcoma. Our findings may shed light on the molecular origins of these rare tumors and how they may relate to other tumors in related kindreds.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2024 ","pages":"2418888"},"PeriodicalIF":0.6,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paraganglioma of the Neck: A Rare Case With Spinal Metastasis. 颈部副神经节瘤：脊柱转移的罕见病例

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2024-04-26 eCollection Date: 2024-01-01 DOI: 10.1155/2024/2025115

Sean McCormack, Eyad Hamad, Amar Hamad

引用次数: 0

The Role of Surgery to Relieve Symptomatic Cutaneous T-Cell Lymphoma Refractory to Medical Treatments. 手术在缓解药物治疗难治性皮肤 T 细胞淋巴瘤症状中的作用。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2024-04-26 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6645278

Wesley Q Zhang, Emily E Hecox, Shireen Dogar, Marc E Walker

{"title":"The Role of Surgery to Relieve Symptomatic Cutaneous T-Cell Lymphoma Refractory to Medical Treatments.","authors":"Wesley Q Zhang, Emily E Hecox, Shireen Dogar, Marc E Walker","doi":"10.1155/2024/6645278","DOIUrl":"https://doi.org/10.1155/2024/6645278","url":null,"abstract":"Background: Though mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), it has no curative treatment. The aim of current topical and systemic treatment is centered around relieving symptoms and optimizing disease-free time. The use of surgical management to achieve the same goals of symptomatic reduction is not well described in the current literature. Methods: We present a case of refractory MF that failed chemotherapy, radiotherapy, and UV light therapy. Despite medical management, the tumor burden progressed to significant compression neuropathy of the ulnar and median nerves. Results: To reduce tumor burden and attempt to provide symptomatic relief, a surgical plan was developed to include radical resection of the tumor of the left upper extremity (LUE) with release of the cubital tunnel, carpal tunnel, Guyon canal, and coverage with split-thickness skin graft. The patient reported decreased symptomatology interfering with her daily activities and, overall, a better quality of life postoperatively. Conclusion: Surgical intervention, in addition to established medical standards of care, for symptomatic relief of compression neuropathy from tumor mass effect for refractory CTCL should be considered to achieve quality of life goals for patients.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2024 ","pages":"6645278"},"PeriodicalIF":0.9,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11068446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report. 阿特珠单抗治疗可能引起的暂时性中性粒细胞减少性免疫相关不良事件后，多关节炎伴活动性腱鞘炎的显著延迟发展：新病例报告。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2024-02-08 eCollection Date: 2024-01-01 DOI: 10.1155/2024/1566299

Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, Ryo Hisada, Mitsuru Sugawara

{"title":"Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report.","authors":"Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, Ryo Hisada, Mitsuru Sugawara","doi":"10.1155/2024/1566299","DOIUrl":"10.1155/2024/1566299","url":null,"abstract":"Immune checkpoint inhibitors have drastically improved cancer treatment. However, they may induce immune-related adverse events (irAEs). Here, we report a case of significantly delayed rheumatic irAEs (Rh-irAEs) with prior possible temporary neutropenic irAEs in a patient with atezolizumab-treated non-small-cell lung cancer and its management. A man in his sixties received atezolizumab monotherapy as the sixth-line treatment. He experienced an infusion-related reaction (fever) during the first cycle. On day 22 of cycle 2, grade 4 neutropenia suddenly appeared, but it disappeared on the next day. Cycle 3 was initiated after seven days; the patient did not exhibit any symptoms for approximately 500 days. However, on day 534 (day 1 of cycle 21), the patient complained of pain in the shoulders, back, and wrists. On day 644, the shoulder and back pain worsened with obvious swelling of the fingers. We thus suspended treatment and consulted a rheumatologist. A diagnosis of polyarthritis with active tenosynovitis was made based on joint ultrasound and laboratory tests. Prednisolone 15 mg attenuated the symptoms, allowing suspension of analgesics; however, dose reduction from 15 mg/day was difficult because of symptom flares. Finally, iguratimod 25 mg twice daily was initiated on day 764; prednisolone was reduced to 10 mg without flares, and its dosage was slowly reduced to 5 mg/day. Although irAEs exhibit multisystem features, delayed development of polyarthritis with active tenosynovitis after possible temporary neutropenic irAEs is rare. Thus, irAEs need to be monitored for a long time in patients with suspected irAE development even if it appears transiently.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2024 ","pages":"1566299"},"PeriodicalIF":0.9,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10869192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer 临床表现为炎症性乳腺癌的转移性卵巢浆液性腺癌

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2024-01-10 DOI: 10.1155/2024/4756335

Lingling Xian, Rachel Hunter, Emily Smith, Rasha Mohammed, C. Madelaire, Guillermo A. Herrera, Rodney E. Shackelford

引用次数: 0

A Rare Case of Nasal Sarcoma with BCOR Internal Tandem Duplication Showing Complete Pathologic Response to the VDC-IE Chemotherapy Protocol. 一例罕见的鼻肉瘤 BCOR 内部串联重复病例对 VDC-IE 化疗方案显示出完全病理反应。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI: 10.1155/2023/5546323

Samer Salah, Maher A Sughayer, Omar Jaber, Nebras Abu Abed, Fatena Ajlouni, Wisam Al Gargaz, Ramiz Abu Hijlih, Fawzi Abuhijla, Akram Al-Ibraheem, Farah Alul, Walid Naser

{"title":"A Rare Case of Nasal Sarcoma with BCOR Internal Tandem Duplication Showing Complete Pathologic Response to the VDC-IE Chemotherapy Protocol.","authors":"Samer Salah, Maher A Sughayer, Omar Jaber, Nebras Abu Abed, Fatena Ajlouni, Wisam Al Gargaz, Ramiz Abu Hijlih, Fawzi Abuhijla, Akram Al-Ibraheem, Farah Alul, Walid Naser","doi":"10.1155/2023/5546323","DOIUrl":"10.1155/2023/5546323","url":null,"abstract":"Sarcoma with BCOR genetic alteration is an exceptionally rare and emerging subtype of sarcoma. It is categorized into two types: BCOR-related gene fusions such as BCOR::CCNB3 sarcomas and other BCOR-rearranged sarcoma and sarcomas with internal tandem duplication of BCOR genes such as infantile undifferentiated round cell sarcomas and primitive myxoid mesenchymal tumors of infancy. BCOR::CCNB3 sarcomas predominantly arise in bone rather than soft tissue and exhibit a higher occurrence in children and adolescent males, whereas sarcomas with BCOR internal tandem duplication show a wider age range but usually arise in the first year of life. Due to their rarity, there is ongoing debate and uncertainty regarding the best treatment approach, with a lack of specific clinical trials addressing these tumors. In this report, we present a unique case of sarcoma with internal tandem duplication of BCOR gene originating in the nasal region. The tumor was successfully and completely resected using the standard VDC-IE chemotherapy protocol, resulting in an unprecedented 100 percent tumor necrosis. The patient has completed the protocol and remains recurrence-free 13 months after diagnosis. This case suggests potential efficacy of the standard VDC-IE protocol in achieving remarkable responses in BCOR rearrangement sarcomas, including the internal tandem duplication subtype. However, further studies are needed to determine the optimal treatment strategies for this disease.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2023 ","pages":"5546323"},"PeriodicalIF":0.9,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10761225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case Report of Probable DRESS Syndrome Associated with Ribociclib. 可能与利博西尼相关的DRESS综合征病例报告。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2023-11-23 eCollection Date: 2023-01-01 DOI: 10.1155/2023/7904950

Florian Carneiro, Marine Bove, Frédérique Beau-Salinas, Tevy San, Pierre Combe

引用次数: 0